Are TFPI and β-TG Indicators of Severity in COVID-19?
Background: In cases of severe coronavirus disease 2019 (COVID-19) affecting the lung, thromboembolic consequences have been described as a major pathologic event that poses a serious risk to life. This is supported by autopsy reports of alveolar destruction and pulmonary intravascular microthrombi. The brand-new coronavirus (CoV) doesn’t seem to have any inherent procoagulant properties. The inflammatory reaction is most likely what caused the coagulation abnormalities in COVID-19. Based on high interleukin-6 levels, COVID-19 exhibits significant inflammation (IL-6). Based on high D-dimer levels, this COVID-19-related inflammation causes coagulopathy (DD). According to COVID-19, an endotheliopathy appears to be a factor in microvascular thrombosis. This study’s objective is to confirm the coagulation anomalies in 100 patients with significant COVID-19 lung involvement and their relationship to the disease’s severity and prognosis.
Method: Indicators of inflammation, endothelial function, and coagulation were measured and compared between patients with severe and mild illness.
Results: Severe COVID-19 patients had higher levels of IL-6, TNF-a, TF, VWF, D-dimer, TAT, and fibrinogen. We also assessed -TG levels that were higher than the plasma levels of PF4 in patients with severe COVID-19, and we found that platelet adhesion was increased. This is because PF4 is rapidly removed from plasma. As compared to moderate COVID-19 patients, all severe COVID-19 patients had shortened CT and CFT, high MCF, and low LY at 30 minutes.
Conclusions: TFPI is said to be a natural anticoagulant that reduces coagulation and inflammation. As a result, we detected TFPI levels that were above normal without causing the inflammation and coagulation to stop, thereby demonstrating the clinical severity of individuals with severe COVID-19.
Author (s) Details
Hemostasis/Hematology Unit, Department of Experimental and Clinical Medicine, University of Catania-95123 Catania, Italy.
Elio Gentilini Cacciola
Policlinico “Umberto I”, Department of Public Health and Infectious Diseases, “Sapienza “ University of Rome-00182 Rome, Italy.
Hemoastasi/Hematology Unit, Medical School of Catania,University of Catania 95123 Catania, Italy.
Hemostasis/Hematology Unit, Department of Medical, Surgical Sciences and Advanced Technologies “G.F. Ingrassia”, University of Catania, 95123 Catania, Italy.
View Book :- https://stm.bookpi.org/CPMS-V6/article/view/7687
Keywords – COVID-19, inflammation, coagulation, TFPI, β-TG